Latest Impairment Charges News

Page 2 of 27
McKesson delivered a strong fiscal second quarter, with revenue up 8% and adjusted diluted EPS rising 18%. The healthcare distributor lifted its full-year adjusted EPS guidance while expanding its specialty-care portfolio through new investments and acquisitions.
Ada Torres
Ada Torres
5 Nov 2026
National Australia Bank’s FY2026 profit fell 9.1% to $6.143 billion as higher credit impairment charges and a $1.347 billion software amortisation charge outweighed stronger lending income. The dividend held at 170 cents per share, while capital buffers improved and management flagged a sharper focus on efficiency and risk control.
Victor Sage
Victor Sage
5 Nov 2026
Cencora delivered a stronger fiscal 2026, with adjusted earnings per share rising 12.3% and quarterly profit benefiting from the OneOncology acquisition. The healthcare distributor expects another 8% to 10% increase in adjusted EPS in fiscal 2027, while reshaping its reporting structure and lifting its dividend.
Ada Torres
Ada Torres
4 Nov 2026
CVS Health plans to separate its healthcare solutions and retail pharmacy businesses by the first half of 2028, while raising its 2026 earnings and cash-flow targets. The announcement came alongside stronger third-quarter results, though management flagged elevated cost trends and potential macroeconomic pressure.
Ada Torres
Ada Torres
4 Nov 2026
Aptiv delivered 2% third-quarter revenue growth and returned to statutory profit, while maintaining its full-year 2026 outlook after the spin-off of its Electrical Distribution Systems business. The result was supported by North American growth and share buybacks, but adjusted EBITDA and margins declined.
Maxwell Dee
Maxwell Dee
4 Nov 2026
Fiserv has reported a US$6.45 billion non-cash goodwill impairment, sending GAAP earnings deeply negative despite adjusted EPS of US$1.75. The payments group reaffirmed its 2026 outlook while doubling its Project Elevate savings target to US$1 billion.
Claire Turing
Claire Turing
4 Nov 2026
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
Westpac’s statutory FY26 profit fell 1% to $6.8 billion, while lending, deposits and underlying operating earnings moved higher. The bank maintained its fully franked final dividend at 77 cents per share, but rising impairment charges and margin pressure remain important counterweights.
Victor Sage
Victor Sage
2 Nov 2026
Far East Gold’s cash position has tightened sharply, with only A$593,000 remaining after a September quarter of takeover costs and exploration spending. The company says it needs new funding while a board-control fight threatens to add further uncertainty.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Ambertech has reported a $2.251 million FY26 statutory loss after taking about $3.2 million in goodwill, inventory and restructuring charges. Cash flow and inventory improved, but the ASX-listed technology distributor will not pay a final dividend as it turns FY27 into an execution test.
Victor Sage
Victor Sage
30 Oct 2026
Lloyds Banking Group delivered a sharp rise in nine-month profit, helped by stronger income, lower remediation costs and improving operating leverage. The UK lender maintained its 2026 targets, while higher impairments and unresolved motor finance litigation remain important caveats.
Victor Sage
Victor Sage
29 Oct 2026
BSP Financial Group delivered unaudited third-quarter net profit after tax of K334 million, up 18% on the comparable quarter and 8% on its first-half quarterly average. Lending, deposits and non-interest income all grew, while capital remained well above regulatory requirements.
Victor Sage
Victor Sage
27 Oct 2026

Browse the archive

Full archive